Breastfeeding and Semaglutide: Is It Safe?

Semaglutide (Wegovy) is not licensed for use while breastfeeding — the effect on breast milk and nursing infants is unknown.
Animal studies have detected semaglutide in breast milk, but no adequate human data exist; the precautionary position is to avoid the combination.
If you stop semaglutide to breastfeed, discuss a restart plan with your prescriber before weaning — weight and metabolic health often need review at that point.
Under-18s are not a licensed population for semaglutide; pregnancy, breastfeeding and trying to conceive are all situations where the medicine should be avoided.

Semaglutide is not recommended during breastfeeding. Current UK guidance advises women to stop semaglutide before breastfeeding or to avoid breastfeeding while taking it, because it is not yet known whether the medicine passes into breast milk or what effect it might have on a nursing infant. This is the clear position of the NHS semaglutide patient information and the medicine's licensed summary of product characteristics. Semaglutide is a prescription-only medicine; any decision about starting, pausing or stopping treatment during this period must be made with your prescriber, GP or specialist, not independently.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

Why breastfeeding changes the semaglutide picture completely

Is semaglutide present in breast milk?

This is a question our prescribers hear most weeks from women who are either just finishing breastfeeding or wondering whether they can resume Wegovy sooner. The honest answer is that human data are genuinely limited. Animal studies suggest that semaglutide, a GLP-1 receptor agonist, can be detected in breast milk, but it is not established at what concentration, how consistently, or whether those amounts would be clinically meaningful for an infant. Because of that gap, the licensed position for semaglutide in the UK is precautionary: breastfeeding and semaglutide treatment should not run alongside each other. The NHS medicines information on semaglutide and the medicine's summary of product characteristics both reflect this clearly. No official UK body currently suggests it is safe to use while nursing, and that position is unlikely to change until adequately powered human studies are completed. If you are in any doubt, the right call is to pause treatment and speak to whoever manages your care.

What should I do if I want to breastfeed while on Wegovy?

If you are currently taking semaglutide and you are breastfeeding, or you are about to start breastfeeding, the practical guidance is to stop semaglutide first and let your prescriber know. Semaglutide has a half-life of approximately one week, so it takes several weeks to clear the body after the final dose; your prescriber can advise on the appropriate washout period in your specific situation. Do not simply stop without letting your clinical team know, partly because stopping abruptly can affect appetite and metabolic control and partly because your prescriber may want to review your wider health picture at that point. NHS England's guidance on weight-management medicines notes that these medicines are not recommended during breastfeeding, alongside similar cautions around pregnancy and trying to conceive. You can read more about the overlap between semaglutide treatment and pregnancy planning on our dedicated Wegovy and pregnancy page. Semaglutide is a prescription-only medicine, and changes of this kind are not something to navigate from the information on a packet alone.

When can I restart semaglutide after I stop breastfeeding?

Once breastfeeding has fully stopped, restarting semaglutide becomes a clinical conversation rather than an automatic step. Many women find that their weight and appetite shift significantly after weaning, and that context matters when deciding whether to restart, at what dose, and under what level of monitoring. If you previously held a prescription through a regulated online pharmacy, you would need a fresh clinical assessment before treatment resumes, at nume, every repeat order goes through clinical review regardless of your history with us. That review is completed the same working day by a GPhC-registered prescriber, not an automated system. If you want to understand the wider treatment landscape before that conversation, the Wegovy treatment overview covers how the medicine works, what the licensed eligibility criteria are, and what to expect from titration. The NHS England guidance on weight-management injections also covers the breastfeeding and conception exclusions clearly for anyone who wants a secondary reference.

Are there other situations where semaglutide is not suitable?

Breastfeeding is one of several situations where the licensed guidance is straightforward: semaglutide should not be used. The same applies to pregnancy and to those who are actively trying to conceive; women who could become pregnant are advised to use reliable contraception during treatment. Semaglutide is not licensed for people under 18. Beyond these absolute positions, there are other health contexts where suitability is a more nuanced clinical judgement, for example, certain gastrointestinal conditions, a personal or family history of medullary thyroid carcinoma, and pancreatitis history all warrant careful prescriber assessment. If you have concerns about how semaglutide interacts with other aspects of your health, our general FAQs cover some of the most common questions, and you can explore specific topics such as semaglutide and alcohol or semaglutide and heart health in more detail, alongside questions about how Wegovy interacts with breastfeeding and whether semaglutide is effective for older patients. For this situation specifically, the safest step is always a direct conversation with a clinician who knows your full history. You can start that process through a free consultation with our prescribers.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions